CXCR4 agonist treatment of hemapoietic cells
First Claim
1. A method of reducing the rate of hematopoietic cell multiplication, comprising administering an effective amount of a CXCR4 agonist to the hematopoietic cells.
2 Assignments
0 Petitions
Accused Products
Abstract
In accordance with various aspects of the invention, CXCR4 agonists, including SDF-1 polypeptides and SDF-1 polypeptide homologues, may be used in reducing the rate of hematopoietic cell multiplication. Methods of the invention may comprise administration of an effective amount of an CXCR4 agonist to cells selected from the group consisting of hematopoietic stem cells and hematopoietic progenitor cells. Cells may be treated in vitro or in vivo in a patient. A therapeutically effective amount of the CXCR4 agonist may be administered to a patient in need of such treatment. Patients in need of such treatments may include, for example patients requiring bone marrow or peripheral blood stem cell transplantation.
-
Citations
26 Claims
- 1. A method of reducing the rate of hematopoietic cell multiplication, comprising administering an effective amount of a CXCR4 agonist to the hematopoietic cells.
-
17. A method of reducing the susceptibility of hematopoietic cells to a cytotoxic agent, comprising administering an effective amount of a CXCR4 agonist to the hematopoietic cells prior to or during exposure of the cells to the cytotoxic agent.
-
23. A CXCR4 agonist peptide comprising:
-
a) an N-terminal sequence homologous to an SDF-1 N-terminal sequence;
b) a C-terminal sequence homologous to an SDF-1 C-terminal sequence or to a MIP-1α
sequence;
c) a peptide spacer sequence linking the N-terminal sequence to the C-terminal sequence, wherein the peptide spacer sequence linking the N-terminal sequence to the C-terminal comprises naturally-occurring amino acids, non-naturally-occurring amino acids, or both naturally-occurring amino acids and non-naturally-occurring amino acids.
-
Specification